Matthew J. Walter

Hematology
660 S Euclid Ave
Saint Louis, MO 63110

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 107 publications

Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.

Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.

Journal: NEJM evidence
Published: August 25, 2026

Long-read cDNA sequencing reveals novel isoforms and spliceosome-mutant-enriched transcripts in AML and MDS.

Long-read cDNA sequencing reveals novel isoforms and spliceosome-mutant-enriched transcripts in AML and MDS.

Journal: bioRxiv : the preprint server for biology
Published: June 04, 2026

A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

Journal: Blood advances
Published: January 23, 2026

Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms.

Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms.

Journal: Blood
Published: January 08, 2026

Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex.

Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex.

Journal: American journal of hematology
Published: December 15, 2025

Exposure to Agent Orange and Association with Myelodysplastic Syndromes.

Exposure to Agent Orange and Association with Myelodysplastic Syndromes.

Journal: Blood advances
Published: December 01, 2025

Exposure to Agent Orange and association with myelodysplastic syndromes.

Exposure to Agent Orange and association with myelodysplastic syndromes.

Journal: Blood advances
Published: December 01, 2025

Sensitivity to ATR-CHK1 pathway inhibition in AML/MDS is enhanced by SRSF2 mutations and reduced by RUNX1 loss.

Sensitivity to ATR-CHK1 pathway inhibition in AML/MDS is enhanced by SRSF2 mutations and reduced by RUNX1 loss.

Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025

A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study.

A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study.

Journal: Blood advances
Published: October 17, 2025

A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study.

A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study.

Journal: Blood advances
Published: October 17, 2025

Clonal hematopoiesis and its progression to myeloid neoplasms: insights into risk, biology, and therapeutic strategies.

Clonal hematopoiesis and its progression to myeloid neoplasms: insights into risk, biology, and therapeutic strategies.

Journal: Haematologica
Published: September 29, 2025

Clonal hematopoiesis and its progression to myeloid neoplasms: insights into risk, biology, and therapeutic strategies.

Clonal hematopoiesis and its progression to myeloid neoplasms: insights into risk, biology, and therapeutic strategies.

Journal: Haematologica
Published: September 29, 2025
Showing 1-12 of 107

Last Updated: 09/26/2026